# Wave Life Sciences, Inc. (WVE) — merger/scheme_of_arrangement [announced]
Source: SEC API (secapi.ai) · situation sit_377e9d5e57e3b2c00cfa · retrieved 2026-08-14T01:29:17.414Z

## Overview
Wave Life Sciences, Inc. is a pharmaceutical company engaged in the development of pharmaceutical preparations.

On August 7, 2026, Wave Life Sciences completed a redomiciliation whereby Wave Life Sciences Ltd. (Singapore) became a wholly owned subsidiary of Wave Life Sciences, Inc. (Delaware). Pursuant to a Scheme of Arrangement, all issued ordinary shares of Wave-Singapore were exchanged on a one-for-one basis for newly issued shares of common stock (par value $0.001 per share) of Wave-Delaware, which became the ultimate parent company of the Wave Life Sciences group.

## Terms
- Counterparty: Wave Life Sciences Ltd. (Singapore) · Consideration: stock

## Key dates
- Announced 2026-08-11

## Timeline
- 2026-08-11 · SCHEDULE 13D/A (0001346824-26-000222): SCHEDULE 13D/A - Wave Life Sciences, Inc. — *Wave Life Sciences, Inc. is a pharmaceutical company engaged in the development of pharmaceutical preparations.* On August 7, 2026, Wave Life Sciences completed a redomiciliation whereby Wave Life Sciences Ltd. (Singapore) became a wholly owned subsidiary of Wave Life Sciences, Inc. (Delaware). Pursuant to a Scheme of Arrangement, all issued ordinary shares of Wave-Singapore were exchanged on a one-for-one basis for newly issued shares of common stock (par value $0.001 per share) of Wave-Delaware, which became the ultimate parent company of the Wave Life Sciences group.
  https://www.sec.gov/Archives/edgar/data/1631574/0001346824-26-000222.txt

## Citations
- 0001346824-26-000222 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000134682426000222